Burcin Sahin

Burcin Sahin

Auto-generated profile, based on publicly available information

Burcin Sahin

Hlth Sci Univ, Clin Infect Dis & Clin Microbiol, Istanbul Training & Res Hosp, Istanbul, Turkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Open access
PDF file
BSBurcın Sahin
Burcın Sahin
SKSennur Kose
Sennur Kose
GEGulhan Eren
Gulhan Eren
GYGulsen Yoruk
Gulsen Yoruk
The aim of the study was to evaluate the clinical features of the patients on hemodialysis with COVID-19 and determine the prognostic factors. In this single center prospective study, a total of 58 chronic renal failure patients on hemodialysis and diagnosed COVID-19 infection were enrolled in the study. The patients were divided into two groups according to their need for intensive care unit referral. Demographic features of the patients, clinical manifestations, laboratory data, treatments, and clinical outcome were evaluated. The mean age of 58 HD patients was 63.2±13.8 (30-93) years and female-male ratio was 0.34. SARS-CoV2-PCR positivity rate was 32.8%. 85.2% of patients (n=46) had bilateral lesions and 14.8% (n=8) had unilateral one lesion in chest CT. The most common symptoms were fatigue (in 44 patients, 80%) and dyspnea (in 31 patients, 56.4%). The most common comorbidity was HT (in 37 patients, 67.3%). The patients who need intensive care and died were older (p=0.015). We observed lower platelet and eosinophil counts, potassium levels, higher AST, troponin and CRP levels in the group of patients who need intensive care and died than the group who survived (p=0.043, p=0.005, p=0.033, p=0.007, p=0,001, p<0.001, respectively) 15.5% of the patients (n=9) were transferred to intensive care unit. Among them, two were discharged with cure and seven patients died. Mortality rate was 12.1%. Older age, lower platelet and eosinophil counts and higher AST, troponin and CRP levels were prognostic risk factors in our hemodialysis patients who needed intensive care.

29 December 2024 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Open access
GYGulsen Yoruk
Gulsen Yoruk
NSNagehan Didem Sari
Nagehan Didem Sari
AİAyşe İnci
Ayşe İnci
GOGulhan Ozdemir
Gulhan Ozdemir
BSBurcin Sahin
Burcin Sahin
Objective: Tuberculosis (TB) is the most important opportunistic infection and one of the leading causes of death in individuals living with human immunodeficiency virus (HIV). Treatment of HIV/TB coinfected patients is more complicated than that of individuals living with HIV only. We aimed to determine the epidemiological characteristics of HIV/TB coinfected patients and the factors affecting TB treatment success. Methods: This retrospective study was conducted between January 2006 and December 2022. Among individuals living with HIV, those aged ≥18 years and with active tuberculosis were included in the study. Sociodemographic, clinical and laboratory findings of HIV/TB coinfected patients were recorded from their files. Patients were divided into two groups according to TB treatment response. The statistical significance level was accepted as p <0.05 in comparison of the two groups. Results: Active TB disease was detected in 78 (%8.4) of 931 individuals living with HIV. A total of 74 patients were included in the study. The average age of the patients was 42.84±12.91 years (range 20-78); 64 (86.5%) were male, and 32 (43.2%) were unemployed. Before TB treatment, 36 (48.6%) of the individuals living with HIV had CD4+ <100 cells/mm3, 10 (13.5%) had negative viral load and only 12 (16.2%) had received antiretroviral treatment (ART). Of these patients, 42 (56.8%) were evaluated as pulmonary TB and 32 (43.2%) as extrapulmonary TB. TB treatment was successful in 49 (%66.2) of the patients; 15 (%20.3) died, 5 (%6.8) received insufficient treatment, 2 (%2.7) were lost to follow-up, and 3 (%4.1) were transferred to another centre. Unsuccessful TB treatment outcomes were associated with a higher mortality rate (20.3%) and increasing age (p<0.05). Conclusion: In our study, the success rate of TB treatment in HIV/TB coinfected individuals was determined as 66.2%. Our findings were lower than World Health Organization targets. The high mortality rate and the advancing age of the patients were determined to be the most critical factors affecting the success of the TB treatment. We conclude that more attention should be paid to HIV/TB coinfected patients, strategies should be developed to ensure early diagnosis, and more comprehensive and prospective studies on this subject need to be conducted in our country.

26 December 2024 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
GYGülşen Yörük
Gülşen Yörük
NSNagehan Didem Sarı
Nagehan Didem Sarı
BŞBurçin Şahin
Burçin Şahin
GÖGülhan Özdemir
Gülhan Özdemir
AKAbdurrahman Kaya
Abdurrahman Kaya

5 May 2021
Verified
Preprint
Open access
BSBurcin Sahin
Burcin Sahin
OOOzen Ayranci Osmanbasoglu
Ozen Ayranci Osmanbasoglu
GEGulhan Eren
Gulhan Eren
GYGülşen Yörük
Gülşen Yörük
Background: The aim of the study was to determine the effectiveness of tocilizumab treatment in patients with COVID-19. Methods: 60 patients infected with SARS-CoV-2 were enrolled in the study. The patients were divided into two groups according to whether they treated with tocilizumab or did not. Demographic and clinical features of the patients, laboratory findings, treatments, and clinical outcome were evaluated. Results: The mean age of 30 patients in group 1 was 63.6±16.3 years and male/female ratio was 3.2, whereas the mean age of 30 patients in group 2 was 59.4±11 years and male/female ratio was 2.7 (P=0.244 and P=0.766, respectively). pO2/FiO2 and lymphocyte count at baseline, 2nd day and 7th day were significantly lower in group 1 treated with standard treatment without tocilizumab than group 2 additionally treated with tocilizumab (P<0.05). D-dimer level at 7th day, ferritin and CRP levels at 2nd and 7th day were significantly higher in group 1 than group 2 (P=0.015, P<0.001, P<0.001, P<0.001, P<0.001, respectively). The patients in group 1 had higher intensive care unit need and mortality rate than the patients in tocilizumab group (P=0.015). 28-day survival was lower in group 1 than tocilizumab group (P=0.024). Conclusions: We observed clinical improvement and lower mortality rate in hospitalized patients with severe COVID-19 with tocilizumab treatment.